Total Cost
Free shipping on all orders

Powered by GeniusRx

brand nevanac 0.1% droptainer

In stock Manufacturer ALCON/NOVARTIS 00065000203
$273.80 / 3 Milliliters Drop Btl

Select Quantity

Prescription is required


Postoperative Ocular Inflammation and Pain

Nepafenac ophthalmic suspension is used for the treatment of pain and inflammation associated with cataract surgery.

Safety and efficacy of topical nepafenac 0.1% ophthalmic suspension have been evaluated in 2 randomized, double-blind, placebo-controlled studies in patients undergoing cataract surgery. In these studies, patients receiving nepafenac (3 times daily beginning 1 day prior to cataract surgery and continuing on the day of surgery and for 2 weeks after surgery) were less likely than those receiving vehicle to have ocular pain and measurable signs of inflammation. About 80 and 50% of patients receiving nepafenac and vehicle, respectively, reported no ocular pain on the day after surgery.

Dosage and Administration


Nepafenac is applied topically to the eye as an ophthalmic suspension. Care should be taken to avoid contamination of the suspension container.

Nepafenac ophthalmic suspension should be shaken well prior to administration. The suspension should not be administered while wearing contact lenses.

Nepafenac ophthalmic suspension may be used in conjunction with other topical ophthalmic medications such as β-adrenergic blocking agents, carbonic anhydrase inhibitors, α-agonists, cycloplegics, and mydriatics. If the patient is receiving more than one topical ophthalmic drug, the drugs should be administered 10 minutes apart from nepafenac administration.


The recommended dosage of nepafenac for the treatment of pain and inflammation associated with cataract surgery in adults and children 10 years of age or older is 1 drop of a 0.1% suspension in the affected eye(s) 3 times daily beginning one day prior to cataract surgery and continuing on the day of the surgery and for 2 weeks after surgery.

Special Populations

No special population recommendations at this time.



Known hypersensitivity to nepafenac or any ingredient in the formulation or to other nonsteroidal anti-inflammatory agents (NSAIAs).




NSAIAs may inhibit platelet aggregation and prolong bleeding time. Some reports indicate that ophthalmic NSAIAs may cause increased bleeding of ocular tissues (including hyphemas) when used in conjunction with ocular surgery. Ophthalmic NSAIAs, including nepafenac, should be used with caution in patients with underlying bleeding tendencies or in those receiving drugs known to prolong bleeding time.

Sensitivity Reactions

Hypersensitivity Reactions

Cross-sensitivity may exist with aspirin, phenylacetic acid derivatives, and other NSAIAs. Nepafenac ophthalmic suspension should be used with caution in patients with a history of hypersensitivity to these drugs. For further discussion of cross-sensitivity of NSAIAs, see Cautions: Sensitivity Reactions in the Salicylates General Statement 28:08.04.24.

General Precautions

Wound-healing Complications

All topical NSAIAs may slow or delay wound healing.(See Drug Interactions: Topical Corticosteroids.)

Ocular Effects

Use of topical NSAIAs may result in keratitis. In some susceptible patients, continued use of topical NSAIAs also may result in epithelial breakdown, corneal thinning, corneal erosion, corneal ulceration, or corneal perforation; these events may be sight-threatening. Patients presenting with evidence of corneal epithelial breakdown should be advised to discontinue topical NSAIA therapy immediately and should be closely monitored for corneal health.

Patients with complicated ocular surgeries, corneal denervation, corneal epithelial defects, diabetes mellitus, ocular surface diseases (e.g., dry eye syndrome), rheumatoid arthritis, or repeat ocular surgeries within a short period of time may be at increased risk for developing adverse corneal effects that may become sight-threatening. Topical NSAIAs should be used with caution in these patients.

Use of topical NSAIAs more than 1 day prior to surgery or use beyond 14 days postoperatively may precipitate or exacerbate adverse corneal effects.

In clinical studies, nepafenac ophthalmic suspension had no substantial effect on intraocular pressure; however, changes in intraocular pressure may occur following cataract surgery.

Specific Populations


Category C. Avoid use in late pregnancy because of known effects on fetal cardiovascular system (possible closure of the ductus arteriosus).


Nepafenac (administered orally as a single 3-mg/kg dose) is distributed into milk in rats. It is not known whether nepafenac is distributed into human milk following topical application to the eye; caution if used in nursing women.

Pediatric Use

Safety and efficacy not established in children younger than 10 years of age.

Geriatric Use

No substantial differences in safety and efficacy relative to younger adults.

Common Adverse Effects

Adverse effects reported in 1% or more of patients receiving nepafenac ophthalmic suspension include capsular opacity, decreased visual acuity, ocular foreign body sensation, increased intraocular pressure, ocular sticky sensation, conjunctival edema, corneal edema, dry eye, lid margin crusting, ocular discomfort, ocular hyperemia, ocular pain, ocular pruritus, photophobia, tearing, vitreous detachment, headache, hypertension, nausea, vomiting, and sinusitis.

Drug Interactions

Drugs Metabolized by Hepatic Microsomal Enzymes

Pharmacokinetic interaction unlikely. Nepafenac did not inhibit the in vitro metabolism of cytochrome P-450 (CYP) isoenzymes 1A2, 2C9, 2C19, 2D6, 2E1, and 3A4.

Protein-bound Drugs

Pharmacokinetic interaction unlikely.

Topical Corticosteroids

Potential pharmacologic interaction (increased potential for wound-healing complications).(See Wound-healing Complications under Warnings/Precautions: General Precautions, in Cautions.)

Write Your Own Review

Your meds on autopilot. Forever.